J&J Rides Standalone Consumer Health Track
J&J takes same approach GSK, Pfizer, Merck & Co, Merck and Novartis have with their consumer health businesses, Bausch Health is starting and Sanofi says it will.
You may also be interested in...
Heiko Schipper, Global Self-Care Federation chairman and Bayer’s consumer health business head, says for some consumers, “it’s this or nothing.” Federation study found between $100bn and $200bn is saved annually worldwide from consumers spending on self-care rather than medical care.
Pharma R&D VP Mathai Mammen acknowledges “pros and cons to remaining” as one company but dismissed “any meaningful downside” for the pharma business, which along with the device business will continue operating as J&J.
While target date for spinning out consumer business into publicly traded company remains some time in 2023, J&J includes additional details on separation timetable with its 2021 full-year and fourth-quarter results.